EURECA Study Update

EURECA is approaching the final steps towards study completion. With all recruitment objectives achieved and most of microbiological confirmation already made, all efforts are now focused on the data-cleaning procedures and final analysis planning.

More than 2000 patients were recruited, with over 1000 carbapenem-resistant strains already processed from 50 sites and 9 European countries, ensuring promising results expected for the next few months.

The team acknowledges the huge effort and commitment of all partners and local investigators in the EURECA study, which made the challenging recruitment objectives possible. The excellent collaboration between the coordination team and the study sites has ensured a smooth run of the study. The EURECA team hopes the results will have a significant impact in the infectious diseases field and future research in Europe and worldwide.

EURECA is a prospective observational study on cohorts of patients with serious carbapenem-resistant Gram-negative bacterial infections. It aims to learn how patients across Europe are infected and currently treated, and which subgroups of patients respond better to which treatments.